What Pharlab Indústria Farmacêutica does

Pharlab Indústria Farmacêutica S/A is a Brazilian pharmaceutical manufacturer founded in 1999, headquartered and operating its primary production facility in Lagoa da Prata, Minas Gerais, with commercial offices in Belo Horizonte and São Paulo. The company produces a broad portfolio spanning branded medicines (Farma), generic drugs, over-the-counter medications (MIP — Medicamento Isento de Prescrição), and dietary supplements (Suplemento Alimentar), covering therapeutic areas including anti-infectives (antibiotics, antivirals, antifungals), anti-inflammatory/analgesics, respiratory/expectorants, dermatologicals, antidiabetics, antianginals, gastrointestinal products, and ADHD treatment. Notable products include Adlyv (ibuprofen 400mg), Escopen Composto (hyoscine + dipyrone), Azitrophar, Doxiclin, Hervirax, Bisolphar, the Agil-C vitamin supplement family, and Vazidin MR (trimetazidine). In 2024, Pharlab obtained ANVISA registration for the first generic ADHD medication in Brazil, and in 2024-2025 acquired the registration rights for Gardenal, Frisium, and Urbanil from Sanofi Medley.

The company manufactures in BPF (Good Manufacturing Practice) certified facilities and distributes through Brazilian pharmacy chains and independent drugstores nationwide, with an exclusive distribution agreement with Moksha8 Brasil for its CNS portfolio (Gardenal, Frisium, Urbanil). It also participates in government procurement and the PROREDE medication donation program for vulnerable populations. Pharlab operates as a subsidiary of the Servier Group, a multinational pharmaceutical conglomerate with operations on five continents, which provides access to international R&D capabilities, quality standards, and regulatory expertise. Revenue is generated through one-time product sales across prescription, generic, OTC, and supplement categories, with pricing governed by ANVISA/CMED frameworks. Customer engagement is supported through an active social media presence (Instagram with 19-32K engagement per post), an institutional content/blog channel, customer service via SAC (0800 037 3322), and community programs including the annual Pharlab Corrida running event held since 2017.

Name

Pharlab Indústria Farmacêutica

Legal name

Pharlab Indústria Farmacêutica S/A

Website

https://pharlab.com.br

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Pharlab Indústria Farmacêutica is a Brazilian pharmaceutical manufacturer founded in 1999 and subsidiary of Servier Group, producing generic, branded, OTC, and dietary supplement products across antibiotics, anti-inflammatories, dermatologicals, antidiabetics, and CNS categories for nationwide pharmacy retail distribution in Brazil.

Ownership category

akta.pro rank

Headquarters

HQ city

Lagoa Da Prata

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales (generic, branded, OTC, supplements): Pharlab generates revenue through the manufacture and sale of pharmaceutical products across four portfolio categories: branded medicines (Farma), generic drugs, OTC/OTC medicines (MIP/Medicamento Isento de Prescrição), and dietary supplements (Suplemento Alimentar). The company sells through pharmacy retail channels and institutional/government buyers. Key therapeutic areas include anti-infectives (antibiotics, antivirals, antifungals), anti-inflammatory/analgesic, respiratory/expectorant, dermatological, antidiabetic, antianginal, and gastrointestinal products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Pharlab Indústria Farmacêutica is a Brazilian pharmaceutical manufacturer that produces and commercializes generic medicines, branded generics, OTC medications (MIP - Medicamento Isento de Prescrição), and dietary supplements. The portfolio spans antibiotics, antivirals, antifungals, anti-inflammatories, corticosteroids, antidiabetics, cardiovascular drugs, respiratory products, and nutritional supplements (including the Agil-C vitamin C gummy family). Products are sold in tablet, capsule, syrup, cream, and ointment forms.

Product overview

Pharlab Indústria Farmacêutica is a Brazilian pharmaceutical company with over 25 years of experience, producing and commercializing a diverse portfolio of generic and brand medications, OTC medicines (MIP), and nutritional supplements. The product portfolio includes: antibiotics (azithromycin/Azitrophar, clarithromycin, ciprofloxacin/Ciproflonax, doxycycline/Doxiclin), antivirals (aciclovir, Hervirax), antifungals (cetoconazol, ciclopirox olamina), anti-inflammatories (Artritec/meloxicam, Farmoxicam/piroxicam), corticosteroids (valerato de betametasona, Dermovat, Cortidex), cardiovascular medications (Vazidin Mr/antianginal), antidiabetics (vildagliptina), antihistamines/analgesics (Escopen Composto, Adlyv/ibuprofen, AgiiGrip DUO), respiratory products (Bisolphar, agiiXpec/expectorants; Agil-Cisteín/mucolytic), nutritional supplements (Agil-C family including Kids and Plus variants), and dermatological products. The company also acquired registration rights for Gardenal, Frisium, and Urbanil from Sanofi Medley. Pharlab pioneered the first generic ADHD medication in Brazil.

Differentiator

Problem solved

Functional benefit

Brands

• Adlyv: Ibuprofen-based analgesic/antipyretic medication for temporary relief of fever and pain.
• Escopen Composto
• Agil-C
• Azitrophar
• Bisolphar

Products and services

• Branded Pharmaceutical Medicines (Farma) Pharlab's branded medicine portfolio including key products such as Adlyv (ibuprofen 400mg), Escopen Composto (butylscopolamine + dipyrone), Azitrophar (azithromycin), Doxiclin (doxycycline), Hervirax (acyclovir), Dermovat (betamethasone valerate), Cortidex, Artritec (meloxicam), Farmoxicam (piroxicam), Vazidin MR (trimetazidine), Elcodrix DC, and AgiiGrip DUO. Distributed via pharmacy retail across Brazil.
• Generic Medicines (Genérico) Generic pharmaceutical portfolio including azithromycin, clarithromycin, ciprofloxacin (Ciproflonax 500mg), doxycycline, aciclovir, cetoconazol cream, ciclopirox olamina, meloxicam, piroxicam, ibuprofen, betamethasone valerate, vildagliptin 50mg, and combination antifungal/antibiotic/corticosteroid creams. Sold through pharmacy retail at accessible price points.
• OTC Medicines (MIP - Medicamento Isento de Prescrição) Over-the-counter (OTC) medications sold without prescription including Adlyv (ibuprofen for fever and pain), Escopen Composto (antispasmodic for cramps), AgiiGrip DUO (flu/cold symptom relief), Elcodrix DC (paracetamol + caffeine analgesic), and agiiXpec (bromhexine expectorant). Targeted at adult consumers seeking self-medication for common ailments.
• Dietary Supplements (Suplemento Alimentar) Nutritional supplements including the Agil-C family of vitamin C gummies (Agil-C 45mg, Agil-C Kids for ages 4-10, Agil-C Kids Plus with vitamin C, D, and zinc), and Agil-Cisteín / Agil-Cisteín Vita C mucolytic supplements containing acetylcysteine. Designed for immune support and respiratory tract care in children and adults.
• First Generic ADHD Medication (Brazil) Pioneering generic ADHD medication launched in 2024. Pharlab became the first manufacturer in Brazil to produce, distribute, and commercialize a generic medication for ADHD treatment, obtaining ANVISA sanitary registration. The product addresses a critical gap in affordable ADHD treatment in the Brazilian market.
• Gardenal, Frisium, and Urbanil (CNS/Neurology Portfolio) CNS/neurology medications acquired via registration transfer from Sanofi Medley Farmacêutica Ltda: Gardenal (antiepileptic, 50mg/100mg tablets and 40mg/20mL oral solution), Frisium (10mg and 20mg, 20 tablets), and Urbanil (10mg and 20mg, 20 tablets). Exclusively distributed in Brazil through Moksha8 Brasil.

Quantifiable outcome

• 55.7% of total waste generated was sent for recycling (2024)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Moksha8 Brasil Indústria e Comércio de Medicamentos LTDAcoreChannel Partner/ Reseller/ Distributor · 4 February 2025Pharlab entered an exclusive distribution agreement with Moksha8 Brasil for the commercialization and distribution of Gardenal, Frisium, and Urbanil products in Brazil. Following the transfer of registration ownership from Sanofi Medley to Pharlab (effective February 2025), Moksha8 became the exclusive distributor handling all commercial operations, consumer support via 0800 601 9392, and customer inquiries at [email protected]. This is a core distribution partnership for Pharlab's CNS/neurology product portfolio.
• PROGEA (Programa da Polícia Militar de Minas Gerais)minorStrategic or Co-development Partner · 1 January 2018Pharlab partners with PROGEA (Polícia Militar de Minas Gerais environmental education program) since 2018 to support environmental education activities in public and private schools in Lagoa da Prata, MG. Pharlab personnel deliver lectures to elementary school children on environmental awareness, sustainability, and fauna/flora preservation, supporting the company's ESG and community engagement objectives.
• ProredeminorStrategic or Co-development PartnerPharlab partners with Prorede for the donation of excess medication inventory to philanthropic organizations and entities serving populations in social vulnerability. This partnership serves dual purposes: avoiding medication waste and providing healthcare access to underserved communities, while also reducing hazardous waste disposal for Pharlab.
• SERVIER GroupcoreOthersPharlab is a member of the SERVIER Group, an international pharmaceutical company with entities across five continents. The privacy policy references data transfers within the SERVIER Group and compliance with LGPD and GDPR regulations. As part of SERVIER, Pharlab benefits from the group's global R&D capabilities, quality standards, and international regulatory expertise, including the development of the pioneering generic ADHD medication.
• Brazilian educational institutions (universities, language schools, specialization programs)minorOthersPharlab maintains partnerships with various educational institutions (universities, language schools, and specialization programs) to provide employees with discounts and special conditions for education and professional development. These partnerships support talent attraction, retention, and workforce skill development as part of Pharlab's human resources strategy.
• CDM (possibly Instituto Brasil/Centro de Desenvolvimento Mineiro)minorStrategic or Co-development PartnerPharlab partnered with CDM to connect more than 400 young people to the pharmaceutical industry, as reported by CDM. This initiative supports youth employment and career development in the pharmaceutical sector.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• EMS Farmacêutica: Brazil's largest pharmaceutical manufacturer by revenue, with a broad generic and branded portfolio across therapeutic areas similar to Pharlab's. Directly competes in the same pharmacy and government channels in Brazil.
• Aché Laboratórios: Leading Brazilian pharmaceutical company with branded, generic, and OTC products across similar therapeutic categories. Operates in the same pharmacy retail channel across Brazil.
• Brainfarma/Teuto: Brazilian generic and OTC pharmaceutical manufacturer with a large multi-therapeutic portfolio distributed through major pharmacy chains in Brazil.
• Eurofarma Laboratórios: Major Brazilian multinational pharmaceutical manufacturer with a generics, branded, and OTC portfolio across multiple therapeutic areas. Comparable in scale and category breadth to Pharlab.
• Medley (Sanofi): Brazilian generic and branded pharmaceutical arm of Sanofi; Pharlab acquired Gardenal, Frisium, and Urbanil registrations directly from Sanofi Medley in 2024–2025, making them both a recent counterparty and a direct generic-market competitor.
• Cristália: Brazilian pharmaceutical manufacturer producing generics, branded, and hospital specialty products. Comparable in scale and product mix to Pharlab in the domestic Brazilian market.
• Biolab Farmacêutica: Brazilian pharmaceutical manufacturer with a generics and branded portfolio focused on prescription and OTC products. Competes with Pharlab in the Brazilian pharmacy and institutional channels.
• Prati-Donaduzzi: One of Brazil's largest generic and OTC manufacturers with broad therapeutic coverage and a strong Brazil-wide distribution footprint in pharmacy chains.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics leader with operations in Brazil. While broader in geographic reach and capabilities than Pharlab, Teva is a relevant incumbent in the same generic pharma category.

Others

• Moksha8 Brasil: Brazilian pharmaceutical distributor that is Pharlab's exclusive distribution partner for Gardenal, Frisium, and Urbanil. Functions as an ecosystem partner rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pharlab
• LinkedInlinkedin.com/company/pharlab-ind-stria-farmac-utica-s-a?trk=top_nav_home
• Instagraminstagram.com/pharlab_oficial

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharlab Indústria Farmacêutica